Because the Right Start Matters Most
OncoHost’s first test, PROphetNSCLC™, guides first-line immunotherapy treatment decisions for advanced, unresectable non-small cell lung cancer patients.
Requiring just one pre-treatment blood test, PROphet® scans approximately 7,000 proteins in a patient's plasma and delivers a report that predicts their clinical benefit probability in response to PD-1/PD-L1 inhibitors.
PROphetNSCLC™ provides clinicians with actionable clinical insights into optimal first-line therapeutic choices, and a better understanding of their patient's personalized cancer dynamics.
The PROphetNSCLC™ test is supported by a blinded validation demonstrating that it accurately predicts a patient’s clinical benefit and associated overall survival differences with single-agent versus combination treatment plans.
The PROphet® model was developed using patient blood samples and clinical data collected within the framework of an ongoing clinical study conducted by OncoHost (PROPHETIC; NCT04056247). In brief, pre-treatment blood samples were collected from 630 advanced-stage non-small cell lung cancer (NSCLC) patients, out of which 545 were receiving PD-1/PD-L1 inhibitors with or without chemotherapy, and 85 were being treated with chemotherapy.
Patient clinical data were recorded, including demographics, clinical characteristics, and clinical benefit. Blood plasma was profiled by the SomaScan® Discovery Assay v4.1, and the resulting proteomic profiles were analyzed in conjunction with patient clinical data. Specifically, a proprietary prediction algorithm was developed to identify proteomic patterns associated with clinical benefit in response to PD-1/PD-L1 inhibitors.
Model development is based on blinded validation
1. Identity differentially expressed proteins: Resistance Associated Proteins (RAPs)
2. Each RAP is an alert that can be either:
3. The collection of “on” and “off” RAPs forms an individual resistance map
Patient A
Higher probability of clinical benefit
Patient B
Lower probability of clinical benefit
The PROphet® report shows a prediction of the patient’s clinical benefit (progression-free survival >12 months) from PD-1/PD-L1 inhibitor immunotherapy-based treatment plans.
Combining these findings with a patient’s PD-L1 level allows for a clear distinction between those who will benefit from immunotherapy alone versus immunotherapy combined with chemotherapy. This may improve the patient’s overall response rate.
PROphet® thereby addresses one of the most common daily dilemmas of the oncologist with an accuracy and level of resolution that simply does not exist today.
POSITIVE or NEGATIVE PROphet® score
Treatment considerations
Clinical evidence
Available treatment options
To date, we do not have a very effective way of predicting response to therapy for these patients. PROphet®️ is an answer to that dilemma. It️ helps me understand just how much therapy I need in my patients with advanced NSCLC and reassures me in my decision-making.
Dr. Jason Porter
PROphet®️ helps guide my treatment decisions by predicting patient response and better understanding how the treatment will work. The test is easy to obtain and reliable.
Dr. Venkat Pavan Kancharla
PROphet®️ is a new technology that allows us to see who will have significant benefit from IO alone, therefore potentially avoiding the need for chemo and over-treating patients.
Dr. Sam Huang
I had a few patients who had high PD-L1, with no response to single-agent Pembro treatment, and with rapidly progressive disease. PROphet®️ has been very helpful in this setting.
Dr. Geeta Kurra
PROphet®️ in my opinion is not only predictive but also prognostic. What stands out about the test is its strong validation process and being quick and easy to obtain.
Dr. Edgardo Santos
To date, we do not have a very effective way of predicting response to therapy for these patients. PROphet®️ is an answer to that dilemma. It️ helps me understand just how much therapy I need in my patients with advanced NSCLC and reassures me in my decision-making.
Dr. Jason Porter
PROphet®️ helps guide my treatment decisions by predicting patient response and better understanding how the treatment will work. The test is easy to obtain and reliable.
Dr. Venkat Pavan Kancharla
PROphet®️ is a new technology that allows us to see who will have significant benefit from IO alone, therefore potentially avoiding the need for chemo and over-treating patients.
Dr. Sam Huang
I had a few patients who had high PD-L1, with no response to single-agent Pembro treatment, and with rapidly progressive disease. PROphet®️ has been very helpful in this setting.
Dr. Geeta Kurra
PROphet®️ in my opinion is not only predictive but also prognostic. What stands out about the test is its strong validation process and being quick and easy to obtain.
Dr. Edgardo Santos
On March 7, 2023, we partnered with the International Society of Liquid Biopsy (ISLB) to discuss unmet needs in predictive immuno-oncology biomarkers.
Prof. David Gandara, MD – The Unmet Need for Predictive Biomarkers of Immunotherapy
Dr. Ofer Sharon - PROphet®: A Plasma Proteomic Predictive Biomarker for Immunotherapy
Prof. David Carbone - PROphet®: Validation & Clinical Utility
Our lab uses high-throughput protein analysis technology to quantify the levels of thousands of proteins in a single plasma sample. The proteins include cytokines, chemokines, growth factors, and enzymes associated with therapy resistance and tumor spread.
The lab is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the Commission on Office Laboratory Accreditation (COLA). The PROphetNSCLC™ test is intended for clinical purposes.
*CLIA number: 34D2250951
Please fill in the form below and we will be in touch to review the PROphetNSCLC™ test ordering process in more detail with you and your staff.
A relevant contact will be in touch soon
